Skip to content

Study · Animal study (in vivo) · rat · 2021

9 results

Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157.

Knezevic M, Gojkovic S, Krezic I, Zizek H, Malekinusic D, Vrdoljak B, Knezevic T, Vranes H, Drmic D, Staroveski M, Djuzel A, Rajkovic Z and 14 more

Show all authors

Kolak T, Lovric E, Milavic M, Sikiric S, Tvrdeic A, Patrlj L, Strbe S, Sola M, Situm A, Kokot A, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P

Biomedicines8 Jul 2021Cited by 34 (Europe PMC)

PMID34356860 (opens in a new tab)PMCIDPMC8301404 (opens in a new tab)DOI10.3390/biomedicines9070792 (opens in a new tab)PepBankPUB-34356860
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

BackgroundWe investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally. As therapy, we hypothesized the rapidly activated alternative bypassing pathways, arterial and venous, and the stable gastric pentadecapeptide BPC 157 since it rapidly alleviated venous occlusion syndromes.MethodsAssessments were performed for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, and oxidative stress), including portal hypertension, caval hypertension, aortal hypotension, and centrally, the superior sagittal sinus hypertension; systemic arterial and venous thrombosis, ECG disturbances, MDA-tissue increase, the multiple organs lesions, heart, lung, liver, kidney and gastrointestinal tract, including brain (swelling, and cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus lesions). Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.ResultsBPC 157 rapidly activated collateral pathways. These collateral loops were the superior mesenteric vein-inferior anterior pancreaticoduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, an alternative pathway toward inferior caval vein via the united middle colic vein and inferior mesenteric vein through the left colic vein, and the inferior anterior pancreaticoduodenal artery and inferior mesenteric artery. Consequently, BPC 157 counteracted the superior sagittal sinus, portal and caval hypertension, aortal hypotension, progressing venous and arterial thrombosis peripherally and centrally, ECG disturbances attenuated. Markedly, the multiple organs lesions, heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain lesions, and oxidative stress in tissues were attenuated.ConclusionsBPC 157 therapy rapidly recovered rats, which have complete occlusion of the superior mesenteric vein and artery.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, BPC‑157 rapidly activated collateral pathways.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 quickly opened bypass routes.

    Peptide
    BPC-157
    Outcome
    IncreaseActivation of collateral pathways
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 rapidly activated collateral pathways.
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, BPC‑157 counteracted superior sagittal sinus hypertension.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 reduced raised pressure in the brain's main vein.

    Peptide
    BPC-157
    Outcome
    DecreaseSuperior sagittal sinus hypertension
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    the superior sagittal sinus, portal and caval hypertension
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, BPC‑157 counteracted portal and caval hypertension.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 reduced raised pressure in two large abdominal veins.

    Peptide
    BPC-157
    Outcome
    DecreasePortal and caval hypertension
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    the superior sagittal sinus, portal and caval hypertension
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, BPC‑157 counteracted aortal hypotension.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 worked against the low aortic pressure.

    Peptide
    BPC-157
    Outcome
    IncreaseAortal hypotension
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 counteracted the superior sagittal sinus, portal and caval hypertension, aortal hypotension
    1 context sentence
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, BPC‑157 counteracted progressing venous and arterial thrombosis peripherally and centrally.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 stopped blood clots from progressing in veins and arteries.

    Peptide
    BPC-157
    Outcome
    DecreaseVenous and arterial thrombosis
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    progressing venous and arterial thrombosis peripherally and centrally
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, ECG disturbances were attenuated with BPC‑157.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 reduced heart rhythm trace disturbances.

    Peptide
    BPC-157
    Outcome
    DecreaseECG disturbances
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    ECG disturbances attenuated.
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, lesions of the heart, lung, liver, kidney and gastrointestinal tract were attenuated with BPC‑157.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 reduced damage to the heart, lungs, liver, kidneys and gut.

    Peptide
    BPC-157
    Outcome
    DecreaseMultiple organ lesions (heart, lung, liver, kidney, gastrointestinal tract)
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Markedly, the multiple organs lesions, heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain lesions, and oxidative stress in tissues were attenuated.
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, brain lesions were attenuated with BPC‑157.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 reduced brain damage.

    Peptide
    BPC-157
    Outcome
    DecreaseBrain lesions
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Markedly, the multiple organs lesions, heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain lesions, and oxidative stress in tissues were attenuated.
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with occluded superior mesenteric vein and artery, oxidative stress in tissues was attenuated with BPC‑157.

    In plain wordsIn rats with blocked abdominal blood vessels, BPC‑157 reduced oxidative stress in tissues.

    Peptide
    BPC-157
    Outcome
    DecreaseTissue oxidative stress
    Study

    ratn: not reported in source

    Occlusion of the superior mesenteric vein and artery
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Markedly, the multiple organs lesions, heart, lung, liver, kidney, and gastrointestinal tract, in particular, as well as brain lesions, and oxidative stress in tissues were attenuated.
    2 context sentences
    Summary · context
    We investigated the occluded essential vessel tributaries, both arterial and venous, occluded superior mesenteric vein and artery in rats, consequent noxious syndrome, peripherally and centrally.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 min ligation-time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.